MARINA KRASITSKAYA: Open Payments
NPI 1508537887 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$622 in 16 payments from 8 companies in 2025. Trend: 2023 $753 · 2024 $635 · 2025 $622
Food & beverage: $427Education: $195
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $147 |
| Janssen Biotech, Inc. | 4 | $129 |
| Incyte Corporation | 1 | $100 |
| SEAGEN INC. | 1 | $95 |
| Merck Sharp & Dohme LLC | 2 | $52 |
| Genmab U.S., Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
Products named: REBLOZYL, ERLEADA, KEYTRUDA QLEX, TALVEY, TECVAYLI, OPDIVO, ORGOVYX, NINLARO.
Industry payments across NY — which companies pay providers there.
